Altamira Therapeutics shares are trading higher after the company announced statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis.
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics announced statistically significant efficacy data from the NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis. This news has led to a rise in the company's share prices.
September 14, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altamira Therapeutics' shares are trading higher after the company announced positive results from the NASAR clinical trial for their Bentrio nasal spray.
The announcement of positive results from a clinical trial typically leads to an increase in a company's share price as it indicates potential future revenue from the product being tested. In this case, the positive results for Altamira Therapeutics' Bentrio nasal spray have led to a rise in the company's share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100